Quantum-Si

Quantum-Si, Inc. develops a protein sequencing platform of proteomics. It offers single molecule analysis, and democratizing its use by providing researchers and clinicians access to the proteome. The company was founded by Jonathan M. Rothberg on June 24, 2013 and is headquartered in Guilford, CT.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Quantum-Si reports mixed Q4 results, eyes growth with Carbon launch

Quantum-Si's Q4 2022 earnings call showcased a mix of financial challenges and operational successes. The company's focus on innovation, product development, and commercialization efforts positions it well for future growth and impact in the healthcare industry.

Quantum-Si reports Q1 revenue growth, plans marketing expansion

Quantum-Si's Q1 2023 performance showed promising revenue and customer orders, but challenges persist with high operating expenses leading to an EBITDA loss. The company's focus on innovation and market expansion presents growth opportunities in the coming quarters.

Quantum-Si faces revenue hurdles in Q2 2023 earnings call

Quantum-Si's Q2 2023 performance showed revenue and gross profit figures, but challenges in meeting expectations led to significant losses. The company's strengths lie in the commercial team's positive feedback and strategic hires, while opportunities exist in realignment and disciplined growth strategies. Addressing revenue challenges, R&D alignment, and customer feedback are key priorities for Quantum-Si.

Quantum-Si (QSI) reports Q3 revenue growth and eyes global expansion

Quantum-Si (QSI) shows promising progress in revenue growth, product innovation, and market interest, despite facing challenges in expenses and profitability.
The company's strategic focus on commercializing key products and expanding internationally presents significant growth opportunities in the coming quarters.
Overall, QSI's financial performance, product roadmap, and market strategies position it for future success, pending effective execution and cost management.

Quantum-Si reports Q4 loss, eyes growth with innovative sequencing

Quantum-Si's Q4 2023 performance reflects a focus on innovation and market expansion despite a net loss, with strong revenue guidance for 2024.
The company's strategic strengths lie in its disruptive technology, product development initiatives, and market positioning in key regions.
Challenges in managing expenses and achieving profitability underscore the need for operational efficiency and competitive differentiation.
Amidst challenges, Quantum-Si has opportunities to drive growth through new product launches, market expansion, and meeting increasing market demand.

Quantum-Si reports revenue growth and strategic priorities for 2024

Quantum-Si's Q2 2024 performance showed revenue growth and improved net loss.
The company's strengths lie in financial reserves, guidance, and strategic priorities.
Challenges include managing expenses and balancing financial strength with innovation.
Opportunities arise from new board additions, technology potential, and market focus.

Quantum-Si reports Q3 revenue miss, eyes growth opportunities ahead

Quantum-Si's Q3 2024 performance reflects revenue challenges but anticipates improvement in Q4, supported by strong cash reserves.
The company's strategic strengths include leadership appointments, industry recognition, and initiatives to drive technology adoption.
Addressing challenges in deal execution, cost management, and revenue generation will be crucial for Quantum-Si's financial health and growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Quantum-Si, Inc. engages in the development of a proprietary universal single-molecule detection platform to enable Next-Generation Protein Sequencing, the ability to sequence proteins in a massively parallel fashion. It can be used for the study of nucleic acids. Its platform includes Carbon automated sample preparation instrument, Platinum NGPS instrument, Quantum-Si Cloud software service, and reagent kits and chips for use with its instruments. The company was founded by Jonathan M. Rothberg on June 24, 2013 and is headquartered in Branford, CT.

Quantum-Si Incorporated (QSI) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.18 per share a year ago.

Quantum-Si Incorporated (QSI) Reports Q2 Loss, Lags Revenue Estimates

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si reports Q2 2024 Operating Results.

Quantum-Si Reports Second Quarter 2024 Financial Results

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si to webcast presentation from the Canaccord 44th Annual Growth Conference.

Quantum-Si to Participate in the Canaccord Genuity 44th Annual Growth Conference

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si to report second quarter 2024 operating results on Wednesday, August 7, 2024.

Quantum-Si to Report Second Quarter 2024 Financial Results on August 7, 2024

Innoviz Technologies

Red Cat Holdings

In most circumstances, you should avoid extremely speculative ideas, especially those billed as cheap penny stocks. It's difficult to find hard statistics regarding the odds of success in this arena, in large part because of the diversity of enterprises and industries involved.

3 Super-Cheap Penny Stocks for the Ultimate Speculator

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced a presentation by Gloria Sheynkman, Ph.D., Assistant Professor in the Department of Molecular Physiology and Biological Physics at the University of Virginia at the Festival of Genomics and Biodata conference being held in Boston on June 12-13, 2024. The presentation, titled “Next Generation Proteomics to Detect Disease-Relevant Proteof.

Quantum-Si Announces Presentation on the Use of Next-Generation Protein Sequencing™ to Detect Disease-Relevant Proteoforms at the Festival of Genomics and Biodata

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces Presentations at ASMS and ESHG.

Quantum-Si Announces Presentations at ASMS and ESHG

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Appoints Former Bio-Techne President and CEO, Chuck Kummeth, to serve as independent Chairman of the Board of Directors.

Quantum-Si Appoints Former Bio-Techne President and CEO, Chuck Kummeth, to serve as independent Chairman of the Board of Directors

Akoya Biosciences Inc

Bionano Genomics

Cytek Biosciences

Danaher

Standard BioTools Inc

908 Devices

Olink Holding AB

Singular Genomics Systems

QIAGEN

Revvity Inc

Seer

Thermo Fisher Scientific

10X Genomics

Lab Instrument and Services providers in the healthcare industry can generate high recurring revenues. Many loss-making instrument makers in the industry may not provide meaningful returns and carry high risks. Cytek stands out as the best opportunity in the sector due to strong growth and manageable losses.

Lab Instrument Industry Update - New Commercial Entrants

Quantum-Si Incorporated (NASDAQ:QSI ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Katherine Atkinson - Senior Vice President-Commercial Marketing Jeff Hawkins - President and Chief Executive Officer Jeff Keyes - Chief Financial Officer Conference Call Participants Swayampakula Ramakanth - HCW Kyle Mikson - Canaccord Genuity Operator Ladies and gentlemen, thank you for standing by. Welcome to the Quantum-Si First Quarter 2024 Earnings Call.

Quantum-Si Incorporated (QSI) Q1 2024 Earnings Call Transcript

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced financial results for the first quarter ended March 31, 2024. Press Release Highlights Reported revenue of $457,000 in the first quarter of 2024 Commenced its full commercial launch of its Platinum® instrument at the end of March 2024 On track to launch version 3 of its sequencing kit, which is expected by the end of Q3 2024 Announced a.

Quantum-Si Reports First Quarter 2024 Financial Results

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced upgrades to its Platinum® Analysis Software to reduce processing time and increase output and precision of Next-Generation Protein Sequencing™ (NGPS) data from the Platinum® instrument. “A core component of our Platinum Analysis Software is a database of predicted kinetic signatures that today, contains nearly two million parameters and.

Quantum-Si Announces Upgrades to Analysis Software that will Provide Customers with Higher Data Output and Precision and Shorter Processing Time

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si to Report First Quarter 2024 Financial Results on May 9, 2024.

Quantum-Si to Report First Quarter 2024 Financial Results on May 9, 2024

Penny stocks are a dime a dozen and come with as much risk because their businesses are unproven; Quantum-Si Incorporated NASDAQ: QSI is not a run-of-the-mill penny stock. Quantum-Si Incorporated manufactures, markets, and supports the Platinum protein sequencer.

Penny Stock Quantum-Si Incorporated Readies For Lift-Off

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced the appointment of Paula Dowdy, a senior executive with more than 35 years of experience across life sciences, enterprise software, and technology industries, to its Board of Directors. Ms. Dowdy currently serves on the Board of Directors for SPT Labtech, a world leading lab automation tools company based in the UK and is an advisor at.

Quantum-Si Appoints Former Illumina and Cisco Systems Executive, Paula Dowdy, to its Board of Directors

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (NASDAQ: QSI): WHAT: The Protein Sequencing Company™, Quantum-Si Incorporated, will showcase its Next-Generation Protein Sequencing™ instrument, Platinum®, and recent enhancements at the 20th Anniversary US HUPO Conference in Portland, Oregon on March 9-13. Additionally, researchers will present data from Platinum and highlight how protein sequencing on the benchtop instrument is providing deeper insights into proteins through streamline.

Quantum-Si and Researchers to Highlight the Power of Next-Generation Protein Sequencing™ on Platinum® at US HUPO Conference

Quantum-Si Incorporated (QSI) Q4 2023 Earnings Call Transcript

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced financial results for the fourth quarter and full year ended December 31, 2023. Press Release Highlights Recorded revenue of $400,000 in the fourth quarter of 2023 as the Company continued its previously communicated controlled commercial launch of its Platinum® instrument Finalizing commercial readiness for expected full commercial la.

Quantum-Si Reports Fourth Quarter and Full Year 2023 Financial Results

--(BUSINESS WIRE)--Quantum-Si Incorporated (NASDAQ: QSI): WHAT: Esteemed scientist Christopher Mason, Ph.D., of Weill Cornell Medicine, is set to discuss his Two Frontiers Project during an exclusive webinar hosted by GenomeWeb. Dr. Mason will also reveal his plans for using Quantum-Si's benchtop protein sequencer, Platinum® to expand his multiomic research on extremophiles and what is needed for human survival in extreme environments. WHY: Dr. Mason recently remarked, “To better understand dis.

Renowned Scientist Christopher Mason, Ph.D. and Quantum-Si Collaborate for Exclusive GenomeWeb Webinar

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it will report financial results for the fourth quarter and full year 2023 on Thursday, February 29, 2024. Company management will host a conference call to discuss financial results and provide a business update on the same day at 4:30 PM ET. Individuals interested in listening to the conference call may do so by joining the live.

Quantum-Si to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced the launch of new platform enhancements for Platinum®, with the release of its new V2 Sequencing Kits. Combined with its first-to-market, next-generation protein sequencer™, these enhancements enable: Increased sequencing performance with assay improvements, including the addition of a new amino acid recognizer; Ability to identify unkn.

Quantum-Si Expands Proteome Coverage and Increases Sequencing Output with New Enhancements to Its Next-Generation Protein Sequencing™ Platform

Quantum-Si is about to move from a controlled launch to a full scale commercial launch of its first product. It will be a groundbreaking device, a desktop Proteome sequencer at a fraction of the price of competing technology. If the product is successful, QSI stock is likely significantly undervalued.

Quantum-Si: Commercial Lift Imminent

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it has entered into an agreement with a new distributor who will make the company's protein sequencing instrument, Platinum® available for the first time in Japan. TOMY Digital Biology Co., Ltd., a renowned importer and distributor with a rich history dating back to the 1950s, will distribute Quantum-Si's next-generation protein se.

Quantum-Si Introduces World's First Next-Generation Protein Sequencer™ in Japan with Addition of New Distributor

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si expands global reach with addition of new distributor.

Quantum-Si Expands Global Reach with Addition of New Distributor

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Adds Distributor ELTA 90 as Demand for Platinum™ Grows.

News for Quantum-Si Stock (QSI)